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Background: The tuberculosis (TB) case detection rate has stagnated at 60% due to disorganized case finding
and insensitivity of sputum smear microscopy. Of the identified TB cases, 4% die while being treated,
monitored with tools that insufficiently predict failure/mortality.
Objective: To explore the TBscore, a recently proposed clinical severity measure for pulmonary TB (PTB)
patients, and to refine, validate, and investigate its place in case finding.
Design: The TBscore’s inter-observer agreement was assessed and compared to the Karnofsky Performance
Score (KPS) (paper I). The TBscore’s variables underlying constructs were assessed, sorting out unrelated
items, proposing a more easily assessable TBscoreII, which was validated internally and externally (paper II).
Finally, TBscore and TBscoreII’s place in PTB-screening was examined in paper III.
Results: The inter-observer variability when grading PTB patients into severity classes was moderate for both
TBscore (kW0.52, 95% CI 0.460.56) and KPS (kW0.49, 95% CI 0.330.65). KPS was influenced by
HIV status, whereas TBscore was unaffected by it. In paper II, proposed TBscoreII was validated internally, in
Guinea-Bissau, and externally, in Ethiopia. In both settings, a failure to bring down the score by ]25% from
baseline to 2 months of treatment predicted subsequent failure (p0.007). Finally, in paper III, TBscore and
TBscoreII were assessed in health-care-seeking adults and found to be higher in PTB-diagnosed patients, 4.9
(95% CI 4.65.2) and 3.9 (95% CI 3.84.0), respectively, versus patients not diagnosed with PTB, 3.0 (95% CI
2.73.2) and 2.4 (95% CI 2.32.5), respectively. Hadwe referred only patientswith cough  2 weeks to sputum
smear,wewouldhavemissed32.1%ofthesmearconfirmedcasesinourcohort.ATBscoreII 2missed8.6%.
Conclusions: TBscore and TBscoreII are useful monitoring tools for PTB patients on treatment, as they could
fill the void which currently exists in risk grading of patients. They may also have a role in PTB screening;
however, this requires our findings to be repeated elsewhere.
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T
uberculosis (TB) is an ancient disease that has
plagued mankind through its existence (1). De-
spite a cure being developed in the 1950s, TB still
ranks number 10 on the list of ‘global death ranks for the
top 25 causes’ (2), and in 2012, nearly 8.6 million people
developed TB, whereas 1.3 million died from the disease
(3). The target of halving TB prevalence by 2015 will not
be reached (3).
Low detection rates and therefore stable sources for
infection, the HIV/AIDS pandemic, low cure rates, and
disorganized and insufficiently resourced TB control pro-
grams (4) maintain the strength of the epidemic. Increas-
ing resistance to currently available anti-TB drugs (5) and
insensitivity of the only widely available diagnostic tool,
sputum smear microscopy (6), have revived research. The
current research focus is mainly directed toward devel-
opment of new drugs and vaccines although there have
been calls for better diagnostic tools (4, 611) and re-
peated propositions to use existing algorithms and tools
to improve case management and detection (12, 13).
A patient diagnosed with pulmonary TB (PTB) is treated
with antibiotics for 6 months. An estimated 4% die while
on treatment (14)  deaths that could have been avoided
if high-risk cases were to be identified early (15).
The aim of this study was to evaluate, refine, and
explore possible applications of the TBscore, a previously
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treatment failure risk for TB patients on treatment.
Background
Clinical prediction rules in general and in TB
Clinical prediction rules (CPRs) use clinical findings to
diagnose a disease or predict an outcome (17). They are
useful when clinicians fail to identify relevant but under-
diagnosed conditions (18) and clinical decision making
is complex (19). Further, they may guide less experienced
examiners (20) through the right diagnostic pathway.
A frequently used CPR in TB is the Karnofsky Perfor-
mance Score (KPS) (21, 22), which has been used as
an indicator for disease severity (23), as treatment re-
sponse measure (24, 25), and to predict mortality (26).
The KPS is a subjective rating tool consisting of per-
formance from 0 to 100% according to the ability to
perform daily activities, to work, need for assistance, and
presence of disease-related symptoms (22).
Table 1 shows CPRs for PTB published over the recent
years; most of them were developed to aid the clinician
to decide if patients admitted to hospitals in low- and
medium-incidence settings should be placed in isolation
(2731). Others are used on initially sputum smear-
negative (SN) patients to improve and accelerate diag-
nosis of PTB (3234). Few have tried to combine signs
and symptoms into a CPR to screen for PTB (3538) and
only two CPRs to monitor TB treatment response have
been proposed (16, 39). Horita et al. (39) suggest a score
consisting of age (in years), oxygen requirement, albumin
concentration (g/dl), and activity of daily living. The
TBscore proposed by Wejse et al. (16) consists of five
symptoms (cough, hemoptysis, dyspnea, chest pain, and
night sweats) and six signs (pale inferior conjunctivae,
pulse  90 per minute, positive finding at lung ausculta-
tion, temperature  378C [axillary], body mass index
[BMI] B18/B16, and mid-upper-arm circumference
[MUAC] B220 mm/B200 mm). Each variable contri-
butes with one point while BMI and MUAC contribute
with an extra point, if B16/B200 mm; hence, the
maximum score 13 (Table 2). The original three severity
classes (SC) were SCI, TBscore 05; SCII, TBscore 67,
and SCIII, TBscore ]8 (16).
Areas of use for the TBscore  stagnated case
detection rates and deaths during treatment
The newest estimates by the WHO state that one third
of all active TB cases are not properly diagnosed and
hence not detected (3). Gold standard for TB diagnosis
is sputum culture. However, most settings are still
relying on sputum smear microscopy (3), a 125-year-
old method which misses half of the cases (6) and even
more if the demand for sputum smears exceed labora-
tory capacity (40). Not finding Mtb in a sputum smear
does not exclude TB as the possible diagnosis (41);
in HIV-infected individuals, the bacteria are often not
found in a sputum smear (42, 43). If SN, the patient is
prescribed antibiotics and/or referred to chest x-ray
(CXR), which is unspecific and hard to interpret for
inexperienced observers, especially if the patient is HIV
co-infected (41, 44). A recently published review on TB
diagnostics states that ‘Simply increasing case detec-
tion rates through existing diagnostics will go a long
way in reducing transmission of PTB’ (12). This, how-
ever, requires an increased awareness toward PTB symp-
toms at health-care facilities and systematic screening
routines.
While on treatment, an estimated 4% of TB patients die
due to the disease, 3% of the HIV-uninfected and 9% of
the HIV-infected patients (14). A previous review found
case fatality rates (CFR) of 1.833% (15). The review em-
phasizes that there is a need to improve recognition of TB
patients at the risk of dying while being treated, stating
that ‘in low-resource settings with strained infrastructure,
development of a simple clinical tool to streamline pri-
oritization of intensified follow-up of high-risk patients
would be of great benefit’ (15).
The current method to evaluate effect of treatment in
PTB patients is repeated sputum smear examinations at
second, fifth, and sixth month of treatment for initially
sputum smear-positive patients (45). This approach has
been shown to be insensitive (4649); finding bacteria in
a sputum smear does not mean that the bacteria found
are viable (50). Also, smear conversion is influenced by
age and height of bacillary load at treatment initiation
(50). Since SN patients are excluded in this recommenda-
tion, the WHO suggests weight gain as prognostic marker
for this group of patients (45). Weight has been shown to
be insufficient in predicting overall outcome (51), since
the patients mostly gain fat mass (52) masking an even-
tual loss of muscle and possibly also organ tissue (53).
Further, there is no clear definition on how to use weight
gain as a prognostic marker (i.e. how much gain is enough).
Aim
The overall aim of the PhD project was to refine and
explore the TBscore to define areas of use.
The specific aims were (Table 3):
. To assess inter-observer variation for the TBscore
used by physicians with different backgrounds and
compare the TBscore to another disease severity
rating tool (i.e. the KPS) (54).
. To further develop and refine the TBscore to
improve inter-observer variation and validate the
proposed TBscoreII internally and externally (55).
. To investigate the performance of TBscore and
TBscoreII and compare them to other PTB screen-
ing tools (56).
Frauke Rudolf
2
(page number not for citation purpose)
Citation: Glob Health Action 2014, 7: 24303 - http://dx.doi.org/10.3402/gha.v7.24303Table 1. Existing CPRs for TB
Authors, year Aim Type of patient Outcome predicted
Aguiar et al. (27) Predictive model for PTB for a more
rational decision on the use of isolation
rooms.
Patients suspected of having TB admitted to
isolation rooms (Cough  2 weeksradiologic
abnormality, or respiratory symptomconfirmed/
suspected HIV-infection).
PTB (Isolation of Mtb in solid culture; findings of
granulomatous inflammation with caseous necrosis
in respiratory tissue biopsy; improvement of
respiratory symptoms within 60 days of TB
treatment.
Rakoczy et al. (28) Stratifying patients suspected of having
TB (use of isolation rooms).
All adult in-patients with newly diagnosed PTB on
the basis of positive results from sputum or
bronchoscopes fluid culture (retrospective).
AFB positive results from sputum or bronchoscopy
fluid culture.
Solari et al. (29) Guides decision to isolate patients with
pulmonary complaints suggestive of
PTB.
Aged 18 yearsproductive cough for ]7 days;
cough of any durationconstitutional symptoms
(fever ]3 days, night sweats, or weight loss ]3
kg in the previous month); hemoptysis or a
differential diagnosis of PTB from the attending
physician.
Culture positive TB.
Wisnivesky et al. (31) Identify early predictors of the need for
respiratory isolation.
Patients with positive culture compared to patients
who had handed in a sputum sample but were
culture negative.
Culture positive PTB.
Alavi-Naini et al. (32) Identify characteristics that identify
individuals with SN PTB.
Negative sputum smears for AFB and remaining
symptomatic after a course of broad spectrum
antibiotics.
Culture confirmed SN PTB.
Mello et al. (33) Predictive model for SN PTB among
outpatients.
Patients with cough ]3 weeks, and two
consecutive samples of spontaneous sputum that
were AFB-negative, or an absence of expectorated
sputum.
Confirmed SN PTB: positive culture for Mtb in
respiratory specimen;
Presumptive SN PTB: clinical improvement after 3
months of anti-TB treatment.
Soto et al. (34) CPR to diagnose SN PTB. Patients admitted to emergency department with
cough ]1 weekone or more of the following:
fever (388C), weight loss (]4 kg in a month),
constitutional symptoms (malaise or hyporexia for
]2 weeks) or dyspnea.
Culture confirmed SN PTB.
Alca ˆntara et al. (35) Identify socio-demographic, clinical, and
behavioral factors that are associated
with PTB.
Older than 14 years of age; having sought medical
attention spontaneously; presenting with cough
]2 weeks; willing to provide at least one sputum
sample and undergo chest X-ray.
Positive culture for Mtb or an AFB-positive sputum
smear; Clinical and radiological characteristics
suggestive of PTBimprovement after 6 months of
anti-TB treatment alone.
Fournet et al. (36) Identify a subgroup of ‘TB suspects’
who qualify for diagnostic investigations.
Male in-mates aged ]18 years. Active TB: sputum smear  culture positive. Or a
positive clinical and radiological response to specific
treatment.
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)Table 1 (Continued)
Authors, year Aim Type of patient Outcome predicted
Corbett et al. (37) Investigate the effect of HIV on the
prevalence of TB symptoms and on the
diagnostic utility of different screening
strategies.
Individuals with current cough, hemoptysis during
the previous year, self-reported fever or ‘hot body’,
night sweats and a subjective report of weight loss,
or who tested positive on sputum culture during
screening (i.e. culture-positive).
Sputum culture  positive for Mtb on two or more
occasions; Failure to respond to broad-spectrum
antibioticsresponse to TB treatment at 1 month;
Culture-negative for Mtbradiological evidence of
TB or the presence of TB-symptoms, failure to
respond to antibioticsresponse to TB treatment at
1 month.
Hanifa et al. (38) Determine prevalence of previously
undiagnosed active TB among ART-
eligible adults. Evaluate the performance
of combinations of symptoms and
standard investigations in the diagnosis
of TB.
ART-eligible (WHO Stage 4 or CD4B200 cells/
mm
3) adults (aged  17 years).
Compatible clinical or radiological features and
sputum culture-positive for Mtb (definite PTB);
Sputum smear-positive, culture-negative (probable
PTB); no other cause of disease foundclinical
improvement after 2 months of anti-TB treatment,
or lost to follow-up or died before 2 months
(possible PTB).
Horita et al. (39) Estimating the prognosis of an individual
TB patient.
Smear positive, HIV uninfected, treatment
susceptible.
Death
Wejse et al. (16) Develop a simple clinical score for
repeated clinical status  evaluation of
TB patients during treatment.
Pulmonary TB patients (smear positive and
negative), HIV-infected and -uninfected.
Change during TB treatment.
Mortality.
TBtuberculosis; PTBpulmonary TB; CPRclinical prediction rule; SNsmear negative; Mtbmycobacterium tuberculosis; AFBacid fast bacilli; ARTanti retroviral treatment;
HIVhuman immunodeficiency virus.
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3Material and methods
Setting and study population
The studies took place at the Bandim Health Project
(BHP) in Bissau, Guinea-Bissau, with an estimated TB
incidence rate of 238/100,000 population and a case de-
tection rate of 56% in 2011 (57).
The BHP is a health and demographic surveillance site
(HDSS) and part of INDEPTH (International Network
for the Demographic Evaluation of Populations and Their
Health in Developing Countries). It has registered around
100,000 people in six suburbs of the capital Bissau since
1978. In 1996, a TB surveillance program was implemen-
ted, registering TB patients living and starting treatment
in the BHP area. Since 2010, adult patients (]15 years)
from the area seeking health care at health centers
and confirming to cough, weight loss, or expectoration
ofsputumareincludedinthePTBsuspects(PTBS)cohort.
Data and applied routines
All patients in the TB cohort in Bissau are followed
throughout their treatment, with clinical controls every
second month.
Data for the study on inter-observer variation were
collected by scoring all patients coming for inclusion or
follow-up visit in separate rooms at the same health
center, within 30 min.
Revision of the TBscore was based on data from
both inpatients and outpatients in Bissau and from adult
TB patients (]18 years) attending the Directly Observed
Treatment Short-course (DOTS) clinic at Gondar Uni-
versity Hospital, Ethiopia. In Ethiopia, the incidence rate
of TB was estimated to be 258/100,000 population and
the case detection rate was 72% in 2011 (58).
To explore the TBscores’ place in case finding, we
collected clinical data from 1,089 PTBS, referring all
consenting PTBS to sputum smear microscopy and HIV-
testing and carrying out a follow-up visit 2 weeks after
the first encounter. If symptoms persisted (i.e. hemoptysis,
persistent cough, or two or more than two of the follow-
ing symptoms: chest pain, dyspnea, night sweats, fever
and/or weight loss), the patient was treated with amox-
icillin (1.5 g/day, for 7 days) and referred to CXR. After
finishing the amoxicillin treatment, another consulta-
tion was carried out by an experienced TB physician
who decided further action; for example, final diagnosis
or a second treatment with erythromycin (1.5 g/day, for
7 days) followed by another CXR and a final diagnosis.
HIV diagnosis
Consenting PTB patients and PTBS from Bissau were
HIV-tested using Determine
TM HIV-1/2 (Alere Inc., MA,
USA) and positive results were confirmed with SD
Bioline HIV 1/2 3.0 (Standard Diagnostics Inc., Korea).
Ethiopian patients were HIV tested as part of provider-
initiated HIV counseling and testing program (PIHCT)
using Determine (HIV-1/2 Ag/Ab Combo, FL, USA),
Capillus (Trinity Biotech USA Inc, NY, USA), and
Unigold (Trinity Biotech USA INC, NY, USA).
Data analysis
All analyses was carried out in Stata Statistical Software
version 11 and 12 (Stata Corporation, TX, USA). All
values are displayed with 95% Confidence Intervals (95%
CI), when applicable. A two-tailed p50.05 was consid-
ered significant.
Inter-observer variation was determined using the
kappa statistic with linear weights, penalizing disagree-
ment in terms of seriousness (59, 60), and ranked accord-
ingtoVieraandGarret(60).Toassesstheratioofvariance
between individuals and the total variance (between
individuals and between measurements), we calculated
the intra-class correlation coefficient (ICC) (61). We
plottedthe differences betweenthetwoobservers’scorings
against their mean in a BlandAltman plot to uncover
potential systematic differences and show the overall
distribution of scores (62, 63).
Refinition of the TBscore was done applying an
exploratory factor analysis (EFA), clarifying the under-
lying structure of the variables (64), which are grouped
according to their clustering pattern, under not measured
underlying constructs (latent factors), with a correlation
of ]0.4 between factor and variable defined as signi-
ficant (64). Responsiveness was evaluated by Cohen’s
effect size (ES), that is, the difference between the mean
baseline and follow-up scores divided by the standard
deviation of the baseline scores and ranked according to
Husted et al. (65).
Table 2. TBscore and TBscoreII.
Score
Variables included TBscore TBscoreII
Symptoms
Cough 1 1
Hemoptysis 1 
Dyspnea 1 1
Chest pain 1 1
Night sweats 1 
Signs
Anemia 1 1
Pulse  90 beats/min 1 
Positive finding at lung auscultation 1 
Temperature  378C1 
BMIB18 1 1
BMIB16 1 1
MUACB220 mm 1 1
MUACB220 mm 1 1
Total number of points possible 13 8
BMIbody mass index; MUACmid upper arm circumference.
The Bandim TBscore
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diagnosis, we used logistic regression analysis. The dis-
criminating ability of significant items with regard to
PTB-diagnosis was assessed with receivers operating
characteristic (ROC) analysis (66). Negative predictive
value, that is, the probability of a suspect in our cohort
not having PTB if the item was absent, and the negative
likelihood ratio (LR), that is, the ratio between the false
negative tests among patients having the disease and
true negative tests among healthy patients, were assessed
to describe the items ability to exclude PTB.
Ethical considerations
The studies were approved by the Ministry of Health
in Guinea-Bissau/the Ethics Committees at Gondar
College of Medical Sciences, Ethiopia, and the Central
Ethical Committee in Denmark. Patients provided oral
andwritteninformedconsentinallstudies;foradolescents
aged 1517, assents from their parents or legal guardian
was required. All participants were offered HIV-testing
with pre- and post-test counseling.
Results
The Bandim TB score: reliability and comparison
with the KPS (54)
The study included 100 PTB patients with a mean age of
33 years (95% CI 3136) and an HIV infection prevalence
of 28%. The analysis was done on 191 double scorings.
The weighted agreement when placing the patients in
SC was moderate for both scores (TBscore: kw0.52
[95% CI 0.450.60]; KPS: kw0.49 [95% CI 0.330.65]).
Agreement between the two observers was assessed for
each variable being part of the TBscore. Almost perfect
agreement was found for cough, MUACB220 mm, and
MUACB200 mm while it was slight for hemoptysis.
Table 3. Overview of the studies constituting the thesis
Study Research question Methodology Results
I: Bandim TB score: reliability
and comparison with the
KPS (54).
Assessing the variability
between two physicians in
performing the Bandim TB
score (TBscore).
To compare the TBscore to
the KPS.
Prospective assessment of the
TBscore and the KPS of 100 PTB
patients at inclusion and/or at
follow-up visits (at second, fourth,
and sixth month of treatment).
Inter-observer variability of the
TBscore varied from slight to
almost perfect.
The grading into severity classes
showed moderate agreement for
TBscore and KPS.
The ICC was larger for the TBscore
than for the KPS.
II: TBscore II: refining and
validating a simple clinical
score for treatment
monitoring of patients with
PTB (55).
Simplify the TBscore,
proposing TBscoreII.
Validate TBscoreII internally
and externally.
EFA on observational data from 565
PTB patients from Bissau.
Validation of TBscore and TBscoreII
with observational data from 488
Guinean and 432 Ethiopian PTB
patients.
Proposal of TBscoreII.
Moderate Cohen’s ES for TBscore-
change in Bissau and large ES in
Gondar between baseline and
second month of follow-up.
Prediction of failure and mortality
by TBscore and TBscoreII,
significant in Bissau.
III: Can TB case-finding among
health-care-seeking adults
be improved? 
Observations from Bissau
(56).
Assess the potential benefit
of elsewhere applied
predictors and TBscore/
TBscoreII, in PTB case
finding.
Observational prospective cohort
study assessing TBscore/TBscoreII
and other clinical predictors in adults
seeking health care for cough,
weight loss and/or sputum
production (PTB suspects).
Cough  2 weeks had the best
diagnostic ability overall.
TBscoreB3 excluded PTB.
A TBscoreII ]3 had largest
diagnostic ability in HIV-infected
patients.
Absence of self-reported weight
loss excluded PTB best in HIV-
infected patients.
Applying cough  2 weeks as
smear microscopy trigger missed
32.1% while applying a TBscoreII
]2 missed 8.6% of the smear
positive PTB cases.
TBtuberculosis; PTB pulmonary TB; KPSKarnofsky Performance Score; ICCintra-class correlation coefficient; ESeffect size;
EFAexploratory factor analysis; HIVhuman immunodeficiency virus.
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tributed betweenall three SCs. However, the KPS scorings
only yielded one observation in SCIII, placing almost
all patients in SCIII.
While 63% (ICC0.632) of the variance in KPSs were
due to true variance, the variance between the observers
when scoring with the TBscore was for 82%, a result of
the true variance between the scored patients (ICC0.822).
The BlandAltman analysis revealed that one observer
gave 25% fewer TBscore-points than the other, whereas
for the KPS one observer gave 1% less (p0.82) points
than the other, indicating a systematic difference between
the observers when scoring with the TBscore.
When assessing the scores’ ability to predict unsuccess-
ful outcome (i.e. treatment failure, death, default), a trend
was seen for the TBscore (p0.082) but not for the KPS
(p0.228).
TBscoreII: refining and validating a simple clinical
score to monitor PTB patients on treatment (55)
Clinical data from 1,070 Guinean and 432 Ethiopian
PTB patients were used to refine the TBscore. While
Ethiopian patients were younger (32 years; 95% CI 30
33) than the patients from Guinea-Bissau (36 years; 95%
CI 3536), had a higher HIV-prevalence (31% vs. 29%,
p0.021), higher percentage of sputum smear positivity
(76% vs. 70%, p0.003), a higher TBscore (7.2; 95%
CI 7.07.5) versus (5.7; 95% CI 5.65.8) and a higher
TBscoreII (4.6; 95% CI 4.54.8) versus (3.6; 95% CI 3.5
3.7), no significant difference was found regarding gender
distribution (41% females vs. 38% males, p0.423) and
successful (completed or cured) treatment outcome (85%
vs. 83%, p0.362).
The underlying pattern of the TBscores variables
was explored in a random sample of 565 PTB patients
from Bissau. It seemed that hemoptysis, pulse, and tem-
perature were not to be part of the construct explained
by the underlying factors. Excluding the items found
to have been agreed on less than substantial in the in-
ter-observer analysis in paper I in addition to the ones
not related to the underlying constructs, we proposed
TBscoreII consisting of cough, dyspnea, chest pain,
anemia, BMIB18, BMIB16, MUACB220 mm, and
MUACB200 mm.
The inter-observer agreement of TBscoreII grading
patients into SC was found to be substantial (kw0.72;
95% CI 0.660.79). The ES was moderate for TBscore
and TBscoreII from baseline to 2-month follow-up in
Bissau while it was large for TBscore and moderate for
TBscoreII in Gondar. From baseline to end of treat-
ment, the ES was large for TBscore and moderate for
TBscoreII in both settings. Failure to decrease TBscore
to ]25% from treatment start to second month of
treatment was significantly associated with subsequent
treatment failure (p0.007 in Bissau and Gondar). For
TBscoreII, the association was significant only in Gondar
(pB0.001). While a failure to decrease TBscore to ]25%
during the first 2 months was significantly associated
(p0.007) with subsequent mortality in Bissau, the
association was significant only for TBscoreII in Gondar
(p0.008).
In both settings, TBscore and TBscoreII at the begin-
ning of treatment were significantly higher in patients
failing on treatment or dying while on treatment (Fig. 1).
Can TB case finding among health-care-seeking
adults be improved? Observations from Bissau (56)
The study cohort consisted of 1,089 patients presenting
with cough and/or weight loss and/or expectoration with
a mean age of 34 years (95% CI 3335 years), and a
HIV-infection rate of 15.1%.
A total of 107 patients were diagnosed with PTB;
76.4% sputum smear positive and 25.2% HIV infected. At
follow-up after 2 weeks from first encounter, symptoms
persisted in 89 (9.7%) of the initially SN or smear
result lacking PTBS. Of those, 82 (92.1%) were treated
with amoxicillin and had a CXR taken before and after.
Following through the algorithm, 11 were diagnosed with
SN PTB, 6 were asymptomatic, 26 did not have PTB, and
in 33 PTB could not be excluded at the second consulta-
tion following amoxicillin treatment. All 33 inconclusive
cases were treated with erythromycin and had a third
CXR taken. The final diagnosis was given at a third
consultation; for 15 it was PTB.
The role of TBscore and TBscoreII in PTB screening
and diagnosis
PTBS diagnosed with PTB had a significantly higher
TBscore (4.9; 95% CI 4.65.2) versus (3.9; 95% CI 3.8
4.0) and TBscoreII (3.0; 95% CI 2.73.2) versus (2.4; 95%
CI 2.32.5) than those not diagnosed with PTB. More
than one third (34.6%) of the PTB diagnosed had a cough
of less than 2 weeks.
A TBscoreII ]3 yielded the largest Area under the
curve(AUC)fortheHIVinfected(0.62;95%CI0.530.72)
while cough  2 weeks reached the largest AUC for the
HIV uninfected (0.68; 95% CI 0.630.74) and the whole
cohort (0.66; 95% CI 0.620.71). Self-reportedweight loss
had the lowest LR in the HIV infected (0.2). For the HIV
uninfected and the whole cohort, a TBscore ]3 resulted
in the lowest LR (0.2 and 0.3, respectively). A TBscoreII
]2 had a LR of 0.4 in the HIV uninfected and the whole
cohort.
Had we used the WHO applied criterion for TB sus-
picion (i.e. chronic cough; cough  2 weeks), almost one
third (32.1%) of the sputum smear positive cases would
have been missed. Among the other predictors, the one
missing the least cases was a TBscore ]3 (6.2%) (Fig. 2).
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In this PhD thesis, it has been shown that TBscore has
a better inter-observer reliability than one of the most
used clinical rating scales in TB research, the KPS. How-
ever,the TBscoreconsisted of signs andsymptomswithan
unknown underlying correlation pattern and with partly
highinter-observer variability, which decreased theoverall
reliabilityof the score. The proposed TBscoreII consists of
relatedandreliablevariables.BothTBscoreandTBscoreII
worked well in two quite different settings when used
to predict failure and mortality. Finally, TBscore and
TBscoreII were shown to be useful in case finding.
TBscore versus KPS in TB
The widest applied rule to assess disease severity and
predict outcome for TB patients is the KPS (22), which is
Fig. 1. TBscore(II) at treatment start and subsequent failure/mortality.
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the same group of patients.
While both scores showed moderate agreement when
used to score the same patient by two observers, the KPS
ratings only fell into two of its three SC, indicating the
inability to distinguish between patients moderately and
seriously affected by PTB. This might be due to more
disease-specific parameters used in TBscore. It has been
postulated earlier that the KPS might not be useful other
than in cancer patients (21, 67). The subjective assess-
ment (i.e. the physician ranking the patient’s subjective
experience of own illness) might obscure disease severity
compared to the more objective and clinically based
nature of the TBscore. This is also supported by the
finding that HIV-status affected the KPS ratings; there
were significantly more HIV-infected patients in the
higher SC, which was not seen for the TBscore. Further-
more, when evaluating the scores prediction of unsuccess-
ful outcome, TBscore showed a trend (insignificant)
toward predicting treatment failure, death, or default,
whereas KPS was unable to do so.
Response of TBscore and TBscoreII to treatment
effect and prediction of failure
The TBscore and TBscoreII worked well in both Ethiopia
and Guinea-Bissau although they were slightly more
responsive to treatment in Ethiopia. This might be due
to the difference in baseline disease severity. The PTB
patients from Ethiopia had a higher TBscore and
TBscoreII at baseline than the Guinean patients, with
the main contributors to higher scores being BMI and
MUAC. It has been shown previously that malnutrition
is more prevalent in Ethiopia than in West Africa (68),
so one might expect higher scores in Ethiopia.
Failure to decrease TBscore/TBscoreII by ]25% was
associated with subsequent failure and mortality; though
not always significant, the trend was seen in both settings
and for both scores. Up to now, the most used predictors
are sputum conversion and weight gain, as recommended
by the WHO (45). It has been shown previously that
sputum conversion has a low sensitivity to predict failure
and the authors conclude that there is a low probability
that a positive sputum smear at any month could cor-
rectly predict failure (47). Weight gain in TB patients
during treatment is deceptive; the weight gained is mostly
due to an increase in fat mass while the loss of muscle
and organ tissue might be ongoing (52, 53). Further the
measure is not well defined and in a previous study it
could not predict outcome when measured at the end of
the first month or the initial 2 months (69).
While this is the first external validation of TBscoreII,
TBscore has been shown to predict poor outcome well in
Ethiopian PTB patients (70).
TBscore versus TBscoreII
Originally, TBscore consisted of five self-reported symp-
toms and six clinically assessed signs with varying relia-
bility when assessed by two independent observers. The
EFA done to uncover underlying constructs revealed
that temperature  378C, pulse, and hemoptysis were
unrelated to the other items. The variables chosen for
TBscoreII are reliable and related; hence, TBscoreII might
be an improved outcome measure, though this was not
as clear in Guinea-Bissau as in Ethiopia. Further, items
requiring medical training (i.e. lung auscultation) and
measures depending upon equipment not always available
at basic health centers (thermometers and 30-second
timers) are excluded in TBscoreII improving its overall
applicability.
TBscore>3
TBscore>4
TBscoreII>2
TBscoreII>3
weight loss
cough>2weeks
0 200 400 600 800 1,000
Total referred
Patients referred
TBscore>3 (100% smear pos, 40% HIV-inf)
TBscore>4 (82% smear pos, 27% HIV-inf)
TBscoreII>2 (70% smear pos, 40% HIV-inf)
TBscoreII>3 (81% smear pos, 10% HIV-inf)
weight loss (80% smear pos, 10% HIV-inf)
cough>2weeks (70% smear pos, 30% HIV-inf)
0 10 20 30 40
Total missed
Cases missed
Patients referred and cases missed
Fig. 2. Referred patients and missed PTB cases using selected predictors as criterion.
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Currently applied indicators for possible PTB infec-
tion (cough  2 weeks for the HIV uninfected (45) and
cough/weight loss/fever/night sweats for the HIV infected
(71)) are insufficient in settings such as Bissau, where
HIV status is often unknown at first encounter and
sputum smear microscopy and CXR are the only avail-
able diagnostic tools.
Acknowledging this, the WHO recently changed its
approach as to when to suspect TB (11), dismissing the
previous focus on chronic cough. However, the current
recommendations are vague and lack structured guidance
for health-care workers in low-resource settings.
A CPR might help the overworked and under experi-
enced nurse or physician to systematically sort out
patients in need for further diagnostic measures. The
diagnostic potential for all investigated tools was better
than chance (i.e. the AUC was higher than 0.5) but none
of them had an AUC above 0.75 which has been stated
to be the threshold value for clinical usefulness (72).
However, we hypothesized that some could hold pre-
dictive ability as to exclude PTB and found that absence
of a TBscore ]3 and self-reported weight loss declined
the possibility of PTB by at least 25% though different in
the HIV infected and the uninfected. The absence of a
TBscore ]2 declined the possibility for PTB by 20% in
the HIV uninfected and the whole cohort. This indicates
that screening with a clinical score consisting of easily
assessable and reliable items might help sort out patients
who do not need referral to further diagnostic tests, that
is, an approach which might improve case finding while
better diagnostic tools are still lacking. Whether TBscore
or TBscoreII should be preferred is not clear from the
present study and requires further research. Although the
applicability is better for TBscoreII, it may have a lower
predictive ability due to fewer included items and it does
not seem to work as well in HIV-infected patients.
Limitations
There is no capacity to carry out diagnostic sputum
culture in Bissau or Gondar; hence, none of the SN PTB
patients are culture confirmed. Nonetheless, all patients
arediagnosedfollowingWHO’sdiagnosticguidelines(73),
and followed through a diagnostic algorithm, which pre-
viously has been shown to have 89% sensitivity and 84%
specificity toward PTB (74). While this reflects reality,
it causes uncertainty in the evaluation of the diagnostic
and predictive abilities of the investigated variables. It
has been postulated that the increase in SN cases due
to HIV could result in over-diagnosing of TB (75). This
would dilute our samples and decrease the predictive and
diagnostic ability of the investigated items.
The PTB patients from Gondar analyzed in paper II
had a higher prevalence of sputum smear-positive PTB
and HIV infection. Though a limitation, it could also be
seen as strength, since TBscore and TBscoreII work well
in both settings despite the differences.
Finally, it can be argued that there might be items
overlooked in the initial variable-selection process. How-
ever, TBscore was developed following guidelines for
score development (76) and the variables were chosen
using the WHO clinical manuals list of important symp-
toms in TB (i.e. variables selected by a group of experts)
(73) taking into account the caveats of using self-reported
variables opposed to objectively measured ones. From the
relevant variables, sputum production, loss of appetite,
and presence of fatigue and clubbing were excluded;
the former three due to missing collection of the data in
the early part of the cohort and clubbing due to its rare
presence (16). Including them may have improved the
TBscore, but it could also have clouded its predictive
ability. Among the originally chosen items, fever (77), low
bodyweight (78, 79), and anemia (80) are well-known
predictors of mortality in TB patients. Though well-
known symptoms in TB patients, neither cough, hemop-
tysis, dyspnea, chest pain, night sweats nor findings at
lung auscultation have been shown to predict mortality.
Among the non-included items, only anorexia has been
shown to associate with mortality (77).
Conclusion and future perspectives
There is a void in the current approach of risk-grading
PTB patients with regard to failure and mortality during
treatment which could be filled by TBscore/TBscoreII.
Thereby, the limited possibilities for a focused follow-up
could be directed toward the ones most in need and
limited resources could be used appropriately.
Further research is needed to elucidate if TBscore/
TBscoreII has a general place in case finding. If our
findings are repeated in other settings, TBscore/TBscoreII
may become part of a future screening-routine, both pas-
sive and active, currently missing and thereby improving
case finding.
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